It is worth mentioning here that even the relatively well‐studied EML‐ALK fusion in non‐small cell lung cancer (Morodomi et al., 2014) or PML‐RAR fusion in acute myelogenous leukemia (Saeed et al., 2011) is only found in 2–5% or 6–10% of these cancers, respectively. Here, ALK is linked to cancer.